Puma Biotechnology (PBYI) Projected to Post Quarterly Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI) is anticipated to issue its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $51.00 million for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Puma Biotechnology Price Performance

NASDAQ PBYI opened at $5.16 on Thursday. Puma Biotechnology has a 1 year low of $2.32 and a 1 year high of $6.07. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.62 and a current ratio of 1.73. The stock has a market capitalization of $259.91 million, a P/E ratio of 5.27 and a beta of 1.39. The business’s fifty day moving average is $5.01 and its two-hundred day moving average is $4.00.

Hedge Funds Weigh In On Puma Biotechnology

Several institutional investors and hedge funds have recently modified their holdings of PBYI. Cerity Partners LLC purchased a new position in shares of Puma Biotechnology during the 2nd quarter valued at $36,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Puma Biotechnology during the 1st quarter valued at $66,000. Invesco Ltd. grew its holdings in shares of Puma Biotechnology by 88.9% during the 1st quarter. Invesco Ltd. now owns 37,631 shares of the biopharmaceutical company’s stock valued at $111,000 after acquiring an additional 17,707 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Puma Biotechnology during the 2nd quarter valued at $135,000. Finally, AQR Capital Management LLC grew its holdings in shares of Puma Biotechnology by 366.5% during the 1st quarter. AQR Capital Management LLC now owns 50,458 shares of the biopharmaceutical company’s stock valued at $149,000 after acquiring an additional 39,641 shares in the last quarter. 61.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on PBYI. Wall Street Zen upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 5th. Weiss Ratings cut shares of Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday, October 25th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.